Denali Therapeutics (DNLI) Total Liabilities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Total Liabilities data on file, last reported at $339.9 million in Q1 2026.

• Quarterly Total Liabilities rose 128.66% year-over-year to $339.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $339.9 million (up 128.66% YoY) and the FY2025 annual result came in at $131.1 million, down 9.28% from the prior year.
• Total Liabilities advanced to $339.9 million in Q1 2026 per DNLI's latest filing, from $131.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $442.6 million in Q1 2023 and bottomed at $115.5 million in Q2 2024.
• The 5-year median for Total Liabilities is $139.2 million (2025), against an average of $226.9 million.
• The widest annual swing landed in 2024, when Total Liabilities plunged 71.62%; it then soared 128.66% in 2026.
• Tracing DNLI's Total Liabilities over 5 years: stood at $417.8 million in 2022, then slumped by 70.57% to $123.0 million in 2023, then grew by 17.51% to $144.5 million in 2024, then fell by 9.28% to $131.1 million in 2025, then jumped by 159.3% to $339.9 million in 2026.
• Per Business Quant, the three latest DNLI Total Liabilities figures stand at $339.9 million (Q1 2026), $131.1 million (Q4 2025), and $129.4 million (Q3 2025).

Peer Comparison